Up­dat­ed: Pfiz­er’s Covid pill pow­ers guid­ance raise, but short­fall else­where rais­es ques­tions

Pfiz­er hasn’t es­caped the volatil­i­ty of its Covid-19 busi­ness — for bet­ter or worse.

Mak­ing its first sub­stan­tive com­ments on the ac­tivist in­vestor push­ing for changes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER